# C3 Glomerulopathy -- A Collaborative Study

> **NIH NIH R01** · UNIVERSITY OF IOWA · 2024 · $629,064

## Abstract

Project Summary/Abstract
 C3 glomerulopathy (C3G) is an aggressive ultra-rare kidney disease that occurs at any age and carries
the highest risk for irreversible renal failure of the known glomerular diseases. It is defined by underlying
complement dysregulation and characterized by predominant complement C3 deposition on kidney biopsy.
Two major disease subgroups are recognized–dense deposit disease (DDD) and C3 glomerulonephritis
(C3GN)–although overlapping clinical and pathological features suggest that C3G is more appropriately
considered a disease continuum. Dysregulation of the alternative pathway (AP) of complement is
fundamental to disease manifestation although terminal pathway dysregulation is also common.
 The estimated renal half-life in C3G patients is 10 years and in patients who progress to end-stage renal
disease (ESRD), transplant decisions, including timing and post-transplant medical therapy, are
overshadowed by the fact that disease recurrence remains a major medical issue. The challenges faced by
clinicians in caring for C3G patients reflect our incomplete understanding of both the underlying
pathophysiology and natural history of this disease. These knowledge gaps impact treatment decisions and
the development of disease-specific therapies.
 In this grant, we propose to:
 • Specific Aim 1. To study the role of genetic variation in C3G
 • Specific Aim 2. To define the characteristics of autoantibodies in C3G by epitope mapping
 • Specific Aim 3. To develop and clinically validate predictive models of disease outcome in C3G
 Completing these specific aims will significantly refine our insight into the pathogenesis of C3G, improve
clinical care of these patients, and lay the foundation for effective and personalized treatments for this
disease.

## Key facts

- **NIH application ID:** 10775742
- **Project number:** 5R01DK110023-07
- **Recipient organization:** UNIVERSITY OF IOWA
- **Principal Investigator:** Patrick Breheny
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $629,064
- **Award type:** 5
- **Project period:** 2017-04-01 → 2027-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10775742

## Citation

> US National Institutes of Health, RePORTER application 10775742, C3 Glomerulopathy -- A Collaborative Study (5R01DK110023-07). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10775742. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*